公开(公告)号：WO2023060308A1

公开(公告)日：2023-04-20

申请号：PCT/AU2022/051227

申请日：2022-10-12

Applicant: MONASH UNIVERSITY

Inventor： DALEY, Stephen Robert ,  GRAS, Stephanie ,  LA GRUTA, Nicole ,  ZAREIE, Pirooz ,  SZETO, Christopher

IPC: C12N15/79 ,  C12N5/0783 ,  C07K14/005 ,  C07K14/47 ,  C07K14/725 ,  A61K35/17 ,  A61K38/00

Abstract: The present invention relates to modified T cell receptors and their uses in treating various diseases or conditions, particularly cancer and autoimmune diseases. A binding protein comprising a variable domain comprising a complementarity-determining region (CDR) capable of contacting a peptide bound to an HLA molecule, wherein the CDR 5 comprises a cysteine capable of forming a disulphide bond with a cysteine in the peptide bound to the HLA molecule, typically wherein the cysteine is introduced into the CDR by mutation or modification of an existing residue.